The results just have to pass a certain threshold. There is no "outstanding" vs "really good" debate in the FDA room in the approval of medicine. Your results are either statistically significant and pass the threshold in the identified markers or they are not. Your drug gets approved or it doesn't.
If this passes P3 (a repeat of P2 results) we win. If this fails P3 it will get hammered unmercilessly.
Share Price, page-152
-
- There are more pages in this discussion • 10,804 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.46 |
Change
0.360(1.79%) |
Mkt cap ! $2.579B | |||
| Open | High | Low | Value | Volume |
| $20.39 | $20.53 | $20.14 | $1.174M | 57.81K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 411 | $20.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.47 | 130 | 4 |
View Market Depth
| Last trade - 12.33pm 26/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |